Overview of key monitoring indicators during molotinib treatment

Molotinib, a new oral JAK1/JAK2 and activin a receptor type 1 inhibitor, has shown significant potential in the treatment of primary myelofibrosis and other diseases. However, in order to ensure patient safety and optimize treatment effects, a series of key indicators must be strictly monitored during the use of molotinib.

The primary concern is monitoring of the platelet complete blood count (CBC). Since molotinib may have an impact on the hematopoietic system, regular CBC testing is crucial for timely detection of potential adverse reactions such as thrombocytopenia. This helps doctors flexibly adjust treatment plans according to the patient's specific conditions to ensure the safety and effectiveness of treatment.

Monitoring of liver function cannot be ignored either. Molotinib is metabolized in the liver and may cause a certain burden on the liver. Therefore, regular liver examinations are necessary before starting treatment and throughout the course of treatment to assess the effects of drugs on the liver and to detect and deal with any potential liver damage in a timely manner.

In addition, monitoring of the risk of infection is also an important part of the use of molotinib. Because this drug may increase a patient's risk of infection, including reactivation of hepatitis B, patients need to pay close attention to signs and symptoms of infection and seek immediate medical attention and receive appropriate treatment if signs occur.

In addition to the above core indicators, doctors will also selectively monitor other related indicators based on the patient's specific situation and clinical performance. For example, for patients who are at risk of malignant tumors, doctors will pay close attention to the progression of the disease; for patients who are at higher risk of cardiovascular events, they will strengthen the monitoring of cardiovascular-related indicators.

Molotinib is not currently on the market in China. Patients who need molotinib can only purchase it from overseas. It is understood that there are related original research versions of molotinib available overseas. The specifications of the original version available overseas are 100mg*30 tablets, and the price is about 220,000 yuan. In addition, there are also related generic versions of molotinib on the market overseas. The price of the generic version of molotinib on the market in Lucius, Laos is less than 3,000 yuan. If patients have more questions about molotinib, they can consult a regular overseas medical consulting company.

To sum up, as a new therapeutic drug, molotinib must strictly monitor a number of key indicators during its use to ensure patient safety. Doctors will develop a personalized monitoring plan based on the patient's specific conditions and flexibly adjust the treatment plan to maximize the therapeutic effect of the drug and reduce the occurrence of adverse events. At the same time, patients should also actively cooperate with doctors’ monitoring and treatment recommendations to jointly ensure the safety and effectiveness of treatment.